Biogen Idec ends collaborative agreement with Proteostasis Therapeutics
Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise
Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises
Essential IR Insights Newsletter - Summer July-August 2023
Insight Weekly: Climate law faces hurdles; US borrowing surges; banks revise uninsured deposits
Proteostasis Therapeutics Inc. is no longer in a partnership to develop treatments for Alzheimer's and Parkinson's diseases with Biogen Idec New Ventures Inc.
Biogen Idec terminated the partnership after Proteostasis failed to produce a lead compound that could be advanced as a drug candidate.
